Mouse Models for Immunotherapy in Hepatocellular Carcinoma

被引:26
|
作者
Li, Enya [1 ,2 ]
Lin, Li [1 ]
Chen, Chia-Wei [1 ]
Ou, Da-Liang [1 ,3 ,4 ]
机构
[1] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei 100, Taiwan
[2] Univ Calif Irvine, Dept Chem & Biomol Engn, Irvine, CA 92697 USA
[3] Natl Taiwan Univ Hosp, Natl Ctr Excellence Clin Trial & Res, Taipei 100, Taiwan
[4] Natl Taiwan Univ, Dept Oncol, Canc Ctr, Taipei 100, Taiwan
关键词
hepatocellular carcinoma; immunotherapy; TUMOR-MICROENVIRONMENT; MURINE MODELS; ANIMAL-MODELS; LIVER-CANCER; BILE-ACID; SORAFENIB; ONCOLOGY; FIBROSIS; INFLAMMATION; PATHOGENESIS;
D O I
10.3390/cancers11111800
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Liver cancer is one of the dominant causes of cancer-related mortality, and the survival rate of liver cancer is among the lowest for all cancers. Immunotherapy for hepatocellular carcinoma (HCC) has yielded some encouraging results, but the percentage of patients responding to single-agent therapies remains low. Therefore, potential directions for improved immunotherapies include identifying new immune targets and checkpoints and customizing treatment procedures for individual patients. The development of combination therapies for HCC is also crucial and urgent and, thus, further studies are required. Mice have been utilized in immunotherapy research due to several advantages, for example, being low in cost, having high success rates for inducing tumor growth, and so on. Moreover, immune-competent mice are used in immunotherapy research to clarify the role that the immune system plays in cancer growth. In this review paper, the advantages and disadvantages of mouse models for immunotherapy, the equipment that are used for monitoring HCC, and the cell strains used for inducing HCC are reviewed.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Advances in Immunotherapy for Hepatocellular Carcinoma
    Hagiwara, Satoru
    Nishida, Naoshi
    Kudo, Masatoshi
    CANCERS, 2023, 15 (07)
  • [42] Potential of immunotherapy for hepatocellular carcinoma
    Breous, Ekaterina
    Thimme, Robert
    JOURNAL OF HEPATOLOGY, 2011, 54 (04) : 830 - 834
  • [43] Advancements in immunotherapy for hepatocellular carcinoma
    Ascari, Sara
    Chen, Rusi
    Vivaldi, Caterina
    Stefanini, Bernardo
    De Sinno, Andrea
    Dalbeni, Andrea
    Federico, Piera
    Tovoli, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2025, 25 (02) : 151 - 165
  • [44] Application of Immunotherapy in Hepatocellular Carcinoma
    Miao, Lele
    Zhang, Zhengchao
    Ren, Zhijian
    Li, Yumin
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [45] Hepatocellular carcinoma in the era of immunotherapy
    Sim, Hao-Wen
    Knox, Jennifer
    CURRENT PROBLEMS IN CANCER, 2018, 42 (01) : 40 - 48
  • [46] Advances in immunotherapy for hepatocellular carcinoma
    Sangro, Bruno
    Sarobe, Pablo
    Hervas-Stubbs, Sandra
    Melero, Ignacio
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2021, 18 (08) : 525 - 543
  • [47] Immunotherapy for recurrent hepatocellular carcinoma
    Ahan Bhatt
    Jennifer Wu
    World Journal of Gastroenterology, 2023, (15) : 2261 - 2271
  • [48] Biomarkers for immunotherapy of hepatocellular carcinoma
    Greten, Tim F.
    Villanueva, Augusto
    Korangy, Firouzeh
    Ruf, Benjamin
    Yarchoan, Mark
    Ma, Lichun
    Ruppin, Eytan
    Wang, Xin W.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (11) : 780 - 798
  • [49] Immunotherapy and transplantation for hepatocellular carcinoma
    Tabrizian, Parissa
    Abdelrahim, Maen
    Schwartz, Myron
    JOURNAL OF HEPATOLOGY, 2024, 80 (05) : 822 - 825
  • [50] Biomarkers for immunotherapy of hepatocellular carcinoma
    Tim F. Greten
    Augusto Villanueva
    Firouzeh Korangy
    Benjamin Ruf
    Mark Yarchoan
    Lichun Ma
    Eytan Ruppin
    Xin W. Wang
    Nature Reviews Clinical Oncology, 2023, 20 : 780 - 798